Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Receivables (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Receivables for 11 consecutive years, with $13400.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables fell 91.88% year-over-year to $13400.0, compared with a TTM value of $13400.0 through Sep 2025, down 91.88%, and an annual FY2024 reading of $188400.0, up 876.17% over the prior year.
  • Receivables was $13400.0 for Q3 2025 at BioRestorative Therapies, down from $15000.0 in the prior quarter.
  • Across five years, Receivables topped out at $188400.0 in Q4 2024 and bottomed at $5000.0 in Q4 2021.
  • Average Receivables over 5 years is $37252.6, with a median of $18000.0 recorded in 2021.
  • The sharpest move saw Receivables skyrocketed 876.17% in 2024, then plummeted 91.88% in 2025.
  • Year by year, Receivables stood at $5000.0 in 2021, then soared by 220.0% to $16000.0 in 2022, then rose by 20.62% to $19300.0 in 2023, then surged by 876.17% to $188400.0 in 2024, then plummeted by 92.89% to $13400.0 in 2025.
  • Business Quant data shows Receivables for BRTX at $13400.0 in Q3 2025, $15000.0 in Q2 2025, and $25000.0 in Q1 2025.